MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Kindly find enclosed30-05-2024
30-05-2024
MARKSANS PHARMA LTD. - 524404 - Corporate Action-Board approves Dividend
The Board has approved final dividend of Rs. 0.60 per equity share30-05-2024
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation on financial results for FY2430-05-2024
MARKSANS PHARMA LTD. - 524404 - Audited Financial Results For FY24
Kindly find enclosed the results for FY2430-05-2024
MARKSANS PHARMA LTD. - 524404 - Board Meeting Outcome for Board Meeting Outcome
Kindly find enclosed the outcome of Board meeting30-05-2024
MARKSANS PHARMA LTD. - 524404 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Kindly find enclosed the secretarial compliance report for the year ended March 31, 202427-05-2024
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Details of investors call as attached17-05-2024
MARKSANS PHARMA LTD. - 524404 - Board Meeting Intimation for Considering And Approving The Audited Financial Results Of The Company (Both Standalone And Consolidated) For The Quarter And Year Ended March 31, 2024 And; Considering Recommendation Of Dividend For FY2023-24
MARKSANS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 ,inter alia, to consider and approve Audited Financial Results of the Company (both Standalone and Consolidated) for the Quarter and year ended March 31, 2024 and; Recommendation of dividend for FY2023-2413-05-2024
Marksans Pharma's Goa Facility Receives Form 483 With Five Observations From U.S. FDA
Marksans Pharma's Goa facility receives Form 483 with five observations from U.S. FDA after routine cGMP inspection.18-04-2024